Vanzacaftor-tezacaftor-deutivacaftor, a novel therapeutic, once-daily drug, demonstrates noninferiority to elexacaftor-tezacaftor-ivacaftor (the twice-daily, standard-of-care drug) in lung function ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Younger patients with cystic fibrosis are to benefit from “life-changing” drugs after regulators authorised their use among babies, toddlers and reception-aged children. Two drugs which have been ...

WASHINGTON (AP) — Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung ...

Cystic fibrosis (CF) is a disease that people can be born with. While there is no cure, people with CF may live well into adulthood if they receive the appropriate treatment and medical monitoring.

According to the Cystic Fibrosis Foundation Patient Registry, more than 70,000 people worldwide are suffering from the disease, with approximately 1,000 new cases diagnosed each year in the United ...

When UNSW Associate Professor Shafagh Waters explains cystic fibrosis (CF) to the children she works with, she asks them to ...

An Otago couple is torn over the decision to invest in fertility treatment for a second child, or making a move to Australia ...

Your body constantly renews your bone tissue in a process called bone turnover or bone remodeling. This process involves resorption (breaking down bone) and then reforming it. In people with cystic ...

(Bloomberg) -- Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth while new drugs’ ...